Enhanced Clinical Trial Design Act of 2017
Latest action · May 4, 2017 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMay 4, 2017
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Enhanced Clinical Trial Design Act of 2017
This bill requires the Food and Drug Administration (FDA), in coordination with the National Institutes of Health, to convene a meeting to discuss clinical trial inclusion and exclusion criteria. The FDA must report on the meeting and issue guidance regarding eligibility criteria for clinical trials.
The Government Accountability Office must report on individual access to investigational drugs for serious conditions through the FDA's expanded access program (i.e., compassionate use).
The FDA must streamline review by institutional review boards of expanded access protocols for individual patients.
The bill amends the Federal Food, Drug, and Cosmetic Act to require the manufacturer or distributor of an investigational drug for a serious condition that is designated a breakthrough therapy, fast track product, or regenerative advanced therapy to publish its expanded access policy not later than 15 days after the designation.Cosponsors 3
Members who signed on, in the order they did. All signed on May 4, 2017.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-CO | Michael F. Bennet | Original | May 4, 2017 |
| R-NC | Richard Burr | Original | May 4, 2017 |
| D-PA | Robert P. Casey Jr. | Original | May 4, 2017 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| Senate | Health, Education, Labor, and Pensions Committee | Referred May 4, 2017 |
Actions 2
Everything that happened, newest first.
- May 4, 2017Introduced in Senate
- May 4, 2017Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Related bills 2
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 934 | FDA Reauthorization Act of 2017 | Related bill | May 11, 2017 |
| HR 2430 | FDA Reauthorization Act of 2017 | Related bill | Aug 18, 2017 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- A bill to expand patient access to experimental treatments in clinical trials, and for other purposes.
- Short Titles as Introduced
- Enhanced Clinical Trial Design Act of 2017
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Administrative law and regulatory procedures
- Congressional oversight
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Food and Drug Administration (FDA)
- Government studies and investigations
- Health
- Medical research
- Public participation and lobbying
Text 1
Each version as it was printed, newest first.
- May 4, 2017Introduced in Senate
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.